{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:48:38Z","timestamp":1786121318018,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cllc.2025.02.013","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:20:02Z","timestamp":1740108002000},"page":"338-346.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series"],"prefix":"10.1016","volume":"26","author":[{"given":"Xiuning","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Eisert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Chun","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal Vivek","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azura","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Siu Hong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"De Bondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gonz\u00e1lez-Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Samol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lye Mun","family":"Tho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Himpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Sen","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty Wai Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Karachaliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soetkin","family":"Vlassak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2025.02.013_bib0001","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.cllc.2021.10.009","article-title":"Overall treatment strategy for patients with metastatic NSCLC with activating EGFR mutations","volume":"23","author":"Hayashi","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.cllc.2025.02.013_bib0002","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC\u2014Current perspectives and future challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.02.013_bib0003","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.cllc.2025.02.013_bib0004","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2025.02.013_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030612","article-title":"MET amplification as a resistance driver to TKI therapies in lung cancer: clinical challenges and opportunities","volume":"15","author":"Qin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2025.02.013_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.965741","article-title":"Case report: success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation","volume":"12","author":"Takamori","year":"2022","journal-title":"Front Oncol"},{"issue":"32","key":"10.1016\/j.cllc.2025.02.013_bib0007","doi-asserted-by":"crossref","first-page":"51311","DOI":"10.18632\/oncotarget.9697","article-title":"The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"7","author":"Gou","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.cllc.2025.02.013_bib0008","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cllc.2025.02.013_bib0009","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.cllc.2025.02.013_bib0010","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14\u2013skipping non\u2013small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2025.02.013_bib0011","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.cllc.2025.02.013_bib0012","article-title":"Long-term efficacy, safety and subgroup analysis of savolitinib in Chinese patients with non-small cell lung cancers harboring MET exon 14 skipping alterations","volume":"3","author":"Lu","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2025.02.013_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101952","article-title":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b\/2 trial","volume":"59","author":"Yu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.cllc.2025.02.013_bib0014","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated or MET-amplified non\u2013small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cllc.2025.02.013_bib0015","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.cllc.2025.02.013_bib0016","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/1078-0432.CCR-22-3318","article-title":"Randomized trial of Tepotinib plus gefitinib versus chemotherapy in EGFR-mutant NSCLC with EGFR inhibitor resistance due to MET amplification: INSIGHT final analysis","volume":"29","author":"Liam","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2025.02.013_bib0017","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib\u202f+\u202fSavolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor\u2013Mutated, MET-amplified non\u2013small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"issue":"suppl_5","key":"10.1016\/j.cllc.2025.02.013_bib0018","first-page":"S949","article-title":"1239P ORCHARD osimertinib\u202f+\u202fsavolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib","volume":"32","author":"Yu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.02.013_bib0019","doi-asserted-by":"crossref","first-page":"S1553","DOI":"10.1016\/j.annonc.2022.10.334","article-title":"305MO SCC244 plus osimertinib in patients with stage IIIB\/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification","volume":"33","author":"Yu","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2025.02.013_bib0020","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.jtho.2022.07.823","article-title":"EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC post-osimertinib","volume":"17","author":"Ahn","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2025.02.013_bib0021","first-page":"e472","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2025.02.013_bib0022","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1078-0432.CCR-19-2860","article-title":"First-in-man Phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2025.02.013_bib0023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1200\/PO.20.00279","article-title":"Phase I\/II study of capmatinib plus erlotinib in patients with MET-positive non\u2013small-cell lung cancer","volume":"5","author":"McCoach","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"31","key":"10.1016\/j.cllc.2025.02.013_bib0024","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.02.013_bib0025","article-title":"A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant non-small-cell lung cancer after development of EGFR-TKI resistance","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2025.02.013_bib0026","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.lungcan.2018.07.030","article-title":"Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses","volume":"124","author":"van Veggel","year":"2018","journal-title":"Lung Cancer"},{"issue":"17","key":"10.1016\/j.cllc.2025.02.013_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713077","article-title":"Real-world data on combined EGFR-TKI and Crizotinib treatment for acquired and de novo MET amplification in patients with metastatic EGFR-mutated NSCLC","volume":"24","author":"Urbanska","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.cllc.2025.02.013_bib0028","article-title":"Brief report: clinical response, toxicity, and resistance mechanisms to osimertinib plus MET inhibitors in patients with EGFR-mutant MET-amplified NSCLC","volume":"4","author":"Wang","year":"2023","journal-title":"JTO Clin Res Rep"},{"issue":"5","key":"10.1016\/j.cllc.2025.02.013_bib0029","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.22.00739","article-title":"Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein-expressing non-small-cell lung cancer","volume":"41","author":"Camidge","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.02.013_bib0030","doi-asserted-by":"crossref","first-page":"S1592","DOI":"10.1016\/j.annonc.2022.10.424","article-title":"387P Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): safety and efficacy results from phase Ib study","volume":"33","author":"Horinouchi","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2025.02.013_bib0031","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cllc.2025.02.013_bib0032","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2025.02.013_bib0033","first-page":"543","article-title":"Lemmens L. Tepotinib: Management of adverse events in patients with MET Exon 14 skipping non-small cell lung cancer","volume":"26","author":"Ahn","year":"2022","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.cllc.2025.02.013_bib0034","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cllc.2022.01.003","article-title":"Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: a clinical review","volume":"23","author":"Cortot","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2025.02.013_bib0035","doi-asserted-by":"crossref","first-page":"S780","DOI":"10.1016\/j.annonc.2023.09.2391","article-title":"1358P Safety of tepotinib\u202f+\u202fEGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC","volume":"34","author":"Nadal","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2025.02.013_bib0036","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2025.02.013_bib0037","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.annonc.2020.03.293","article-title":"Molecular correlates of response to capmatinib in advanced non\u2013small-cell lung cancer: clinical and biomarker results from a Phase I trial","volume":"31","author":"Schuler","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:50:08Z","timestamp":1786074608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525730425000439"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.02.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}